What is surfactant protein deficiency?
Surfactant is a thin film of fats and proteins that lines the air sacs (alveoli) of the lungs. It lowers surface tension so that the air sacs stay open at the end of each breath. Without working surfactant, the lungs become stiff, the air sacs collapse and oxygen cannot pass easily into the blood.
Surfactant protein deficiency, more accurately called genetic surfactant dysfunction, is a group of ultra-rare inherited conditions caused by changes in the genes that make or process surfactant. The main genes involved are SFTPB (surfactant protein B), SFTPC (surfactant protein C), ABCA3 (a transporter that packages surfactant) and NKX2-1 (a gene that controls lung, thyroid and brain development). Rarer variants in SFTPA1 and SFTPA2 can cause lung fibrosis in adults.
These conditions are different from the temporary surfactant shortage seen in premature babies, which improves as the lungs mature. Genetic surfactant dysfunction is lifelong and is one of the recognised causes of childhood interstitial lung disease.
Symptoms at different ages
The pattern of illness depends largely on which gene is affected and how severe the change is.
Newborns
Complete SP-B deficiency and severe ABCA3 variants usually cause breathing difficulty within hours of birth in a full-term baby, with rapid breathing, grunting, chest indrawing and low oxygen levels that do not settle with the usual treatment for newborn respiratory distress.
Infants and children
Milder forms appear later as childhood interstitial lung disease. Typical features are:
- Fast or laboured breathing, even at rest
- Poor feeding and failure to gain weight
- Persistent dry cough
- Low oxygen levels, especially during sleep or feeding
- Finger clubbing in longer-standing disease
Adults
SFTPC, ABCA3 and SFTPA variants can first come to light in adult life as progressive breathlessness and lung fibrosis, sometimes resembling idiopathic pulmonary fibrosis. A family history of lung fibrosis at a young age is an important clue. NKX2-1 variants may also cause underactive thyroid and movement problems (chorea) alongside lung disease.
Causes and inheritance
These conditions are caused by inherited or newly arising gene changes, not by infection, pollution or anything the parents did during pregnancy. The way they pass through families differs by gene:
| Gene | Inheritance and usual pattern |
|---|---|
| SFTPB | Recessive (both parents are healthy carriers), usually severe newborn disease |
| ABCA3 | Recessive, ranging from fatal newborn disease to milder childhood or adult lung disease |
| SFTPC | Dominant or newly arising, variable from infancy to adult lung fibrosis |
| NKX2-1 | Dominant or newly arising, with lung, thyroid and nervous system involvement |
Recessive conditions are more likely when parents are related by blood, which is relevant in some communities in India. Viral infections and cigarette smoke exposure can worsen existing disease.
How surfactant disorders are diagnosed
Diagnosis relies on recognising the pattern and confirming it with genetic testing.
| Test | What it shows |
|---|---|
| Genetic testing (gene panel or exome) | The specific gene change, which confirms the diagnosis and guides family counselling |
| High-resolution CT chest | Ground-glass shadowing, thickened septa and, over time, small cysts or fibrosis |
| Oxygen saturation and sleep oximetry | The degree of oxygen shortage, including at night |
| Lung function tests (older children and adults) | A restrictive pattern and reduced gas transfer |
| Thyroid function tests | Hypothyroidism linked to NKX2-1 variants |
| Lung biopsy | Reserved for cases where genetic tests are inconclusive |
Other causes of childhood interstitial lung disease, recurrent infection, aspiration, heart disease and immune deficiency are considered and excluded.
Treatment
There is no treatment yet that corrects the faulty gene, so care focuses on supporting breathing, slowing lung damage and planning ahead. Children are managed jointly with paediatric pulmonology, with input from genetics, neonatology, endocrinology and transplant centres as needed.
Supportive care
- Supplemental oxygen, including during sleep and feeding
- Nutritional support to maintain growth
- Vaccination, including influenza and pneumococcal vaccines, and prompt treatment of chest infections
- A completely smoke-free home
Anti-inflammatory treatment
Hydroxychloroquine, azithromycin and systemic corticosteroids are used in some children and adults. Evidence comes mainly from case series and small trials, so treatment is individualised and monitored closely for benefit and side effects. In adults with progressive fibrosis, antifibrotic drugs may be discussed.
Lung transplantation
Complete SP-B deficiency and the most severe ABCA3 forms are usually fatal in infancy without lung transplantation. Transplant referral is also considered for older children and adults with advanced, progressive disease.
Outlook and family planning
The outlook varies widely. Some children with SFTPC or milder ABCA3 variants stabilise or improve as they grow, while others develop progressive fibrosis. Regular follow-up with oxygen checks, growth monitoring, lung function and periodic imaging helps detect change early.
Genetic counselling is offered to every family. Once the gene change is known, parents can be told the chance of it recurring in a future pregnancy, and relatives can be tested where appropriate.
When to seek urgent care
Seek emergency care if a baby or child breathes very fast or with visible effort, has blue lips or tongue, stops feeding, becomes drowsy or pauses in breathing. Adults should seek urgent help for breathlessness at rest, falling oxygen readings on a home oximeter, or chest infection with fever and worsening breathing.
Frequently asked questions
Is surfactant protein deficiency the same as the breathing problem in premature babies?
No. Premature babies often lack enough surfactant simply because their lungs are immature, and this improves with time and treatment. Genetic surfactant dysfunction is an inherited, lifelong condition that can affect full-term babies, children and adults.
Can surfactant given to premature babies treat genetic surfactant deficiency?
Replacement surfactant may give brief improvement in newborns but does not provide lasting benefit in genetic surfactant disorders, because the lungs cannot keep producing normal surfactant.
Will my other children be affected?
It depends on the gene. In recessive conditions such as SP-B and ABCA3 deficiency, each pregnancy of carrier parents has a one in four chance of an affected child. In dominant conditions such as SFTPC, an affected parent has a one in two chance of passing it on. Genetic counselling explains your family's specific risk.
Can adults have surfactant gene disorders?
Yes. Some SFTPC, ABCA3 and SFTPA variants first cause lung fibrosis in adult life, sometimes in several members of a family. Genetic testing is considered when fibrosis occurs at a young age or runs in a family.
Is lung transplantation possible?
Lung transplantation is the only definitive option for the most severe forms and for advanced progressive disease. Suitability is assessed at a specialist transplant centre.
Is the condition contagious?
No. Surfactant disorders are genetic and cannot be passed on through contact, coughing or sharing a home.
Related conditions and procedures
Consult Dr. Gogineni Ratnakara Rao
Apollo Hospitals, Financial District: Monday to Saturday, 8:30 AM to 5:00 PM. Anything in Lung Clinic, Chanda Nagar: Monday to Saturday (Thursday closed), 6:00 PM to 9:00 PM.